Amino acid insertions near gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors

Journal of Virology

Volumn 78, Issue 21, 2004, Pages 12030-12040

  Tamiya, Sadahiro ^a   Mardy, Sek ^a   Kavlick, Mark F ^a   Yoshimura, Kazuhisa ^b   Mistuya, Hiroaki ^a,b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMINO ACID; DELAVIRDINE; EFAVIRENZ; GAG PROTEIN; HYDROXYUREA; INDINAVIR; LAMIVUDINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; ENZYME ACTIVITY; GENE INSERTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; BASE SEQUENCE; DRUG RESISTANCE, MULTIPLE, VIRAL; GENE PRODUCTS, GAG; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 6344249119     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.21.12030-12040.2004     Document Type: Article

References (43)

1. Abbotts, J., K. Bebenek, T. A. Kunkel, and S. H. Wilson. 1993. Mechanism of HIV-1 reverse transcriptase. Termination of processive synthesis on a natural DNA template is influenced by the sequence of the template-primer stem. J. Biol. Chem. 268:10312-10323.
2. Bebenek, K., J. D. Roberts, and T. A. Kunkel. 1992. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem. 267:3589-3596.
3. Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
4. Brenner, B. G., J. P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Detorio, B. Spira, V. Essabag, B. Conway, R. Lalonde, R. P. Sekaly, and M. A. Wainberg. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 76:1753-1761.
5. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Tepplert, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
6. Cote, H. C., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
7. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
8. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. 2003. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [Online.] http://aidsinfo .nih.gov/guidelines/adult/archive/AA_071403.html.
9. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
10. Ermolieff, J., X. Lin, and J. Tang. 1997. Kinetic properties of saquinavir resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. Biochemistry 36:12364-12370.
11. Falloon, J., S. Piscitelli, S. Vogel, B. Sadler, H. Mitsuya, M. F. Kavlick, K. Yoshimura, M. Rogers, S. LaFon, D. J. Manion, H. C. Lane, and H. Masur. 2000. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. 30:313-318.
12. Fang, G., B. Weiser, A. Visosky, T. Moran, and H. Burger. 1999. PCR mediated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA. Nat. Med. 5:239-242.
13. Gallego, O., C. de Mendoza, A. Corral, and V. Soriano. 2003. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J. Clin. Microbiol. 41:1245-1247.
14. Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Cote, R. L. Rich, D. G. Myszka, and W. I. Sundquist. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65.
15. Gatanaga, H., Y. Suzuki, H. Tsang, K. Yoshimura, M. F. Kavlick, K. Nagashima, R. J. Gorelick, S. Mardy, C. Tang, M. F. Summers, and H. Mitsuya. 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277:5952-5961.
16. Grabar, S., C. Pradier, E. Le Corfec, R. Lancar, C. Allavena, M. Bentata, P. Berlureau, C. Dupont, P. Fabbro-Peray, I. Poizot-Martin, and D. Costagliola. 2000. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 14:141-149.
17. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287.
18. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C. M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
19. pol genes under highly active antiretroviral therapy. Microbiol. Immunol. 47:71-79.
20. Iversen, A. K., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
21. Kavlick, M. F., and H. Mitsuya. 2001. The emergence of drug-resistant HIV-1 variants and impact on antiretroviral therapy of HIV-1 infection. p. 279-312. In E. De Clarcq (ed.), Art of antiretroviral therapy. American Society for Microbiology, Washington, D.C.
22. Kosalaraksa, P., M. F. Kavlick, V. Maroun, R. Le, and H. Mitsuya. 1999. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J. Virol. 73:5356-5363.
23. Kuiken, C., B. Foley, B. P. M. Hahn, P. Marx, F. McCutchan, J. Mellors, J. Mullins, S. Wolinsky, and B. Kober. 2000. HIV Sequence compendium. Los Alamos National Laboratory, Los Alamos, N. Mex.
24. Mahalingam, B., J. M. Louis, C. C. Reed, J. M. Adomat, J. Krouse, Y. F. Wang, R. W. Harrison, and I. T. Weber. 1999. Structural and kinetic analysis of drug-resistant mutants of HIV-1 protease. Eur. J. Biochem. 263:238-245.
25. Mammano, F., C. Petit, and F. Clavel. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632-7637.
26. Mitsuya, H., and J. W. Erickson. 1999. Discovery and development of antiretroviral therapeutics for HIV infection, p. 751-780. In T. C. Merigan, J. G. Bartlet, and D. Bolognes (ed.), Textbook of AIDS medicine. The Williams & Wilkins Co., Baltimore, Md.
27. Parades, R., A. Mocroft, O. Kirk, A. Lazzarin, S. E. Barton, J. van Lunzen, T. L. Katzenstein, F. Antunes, J. D. Lundgren, and B. Clotet. 2000. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the Euro-SIDA study. Arch. Intern. Med. 160:1123-1132.
28. Peters, S., M. Munoz, S. Yerly, V. Sanchez-Merino, C. Lopez Galindez, L. Perrin, B. Larder, D. Cmarko, S. Fakan, P. Meylan, and A. Telenti. 2001. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J. Virol. 75:9644-9653.
29. Pettit, S. C., M. D. Moody, R. S. Wehbie, A. H. Kaplan, P. V. Nantermet, C. A. Klein, and R. Swanstrom. 1994. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:8017-8027.
30. Pornillos, O., S. L. Alam, D. R. Davis, and W. I. Sundquist. 2002. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat. Struct. Biol. 9:812-817.
31. Preston, B. D., B. J. Poiesz, and L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
32. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
33. Rose, R. E., Y. F. Gong, J. A. Greytok, C. M. Bechtold, B. J. Terry, B. S. Robinson, M. Alam, R. J. Colonno, and P. F. Lin. 1996. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
34. Schock, H. B., V. M. Garsky, and L. C. Kuo. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials: compensatory modulations of binding and activity. J. Biol. Chem. 271:31957-31963.
35. Shafer, R. W., M. J, Kozal, M. A. Winters, A. K. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer, III, P. Gupta, S. Rasheed, R. Coombs, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
36. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
37. Shirasaka, T., R. Yarchoan, M. C. O'Brien, R. N. Husson, B. D. Anderson, E. Kojima, T. Shimada, S. Broder, and H. Mitsuya. 1993. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA 90:562-566.
38. Stanford University Medical Center. Stanford HIV drug resistance database. [Online.] http://hivdb.stanford.edu. Stanford University Medical Center, Stanford, Calif.
39. Ueno, T., T. Shirasaka, and H. Mitsuya. 1995. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J. Biol. Chem. 270:23605-23611.
40. Winters, M. A., K. L. Coolley, Y. A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, and T. C. Merigan. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 102:1769-1775.
41. Yeni, P. G., S. M. Hammer, C. C. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2002. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288:222-235.
42. Yoshimura, K., R. Kato, K. Yusa, M. F. Kavlick, V. Maroun, A. Nguyen, T. Mimoto, T. Ueno, M. Shintani, J. Falloon, H. Masur, H. Hayashi, J. Erickson, and H. Mitsuya. 1999. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. USA 96:8675-8680.
43. Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.